10 September 2012
Boehringer Ingelheim implements flexible fully disposable up- and downstream manufacturing for biopharmaceuticals
Ingelheim,Germany, 10 September 2012 –Boehringer Ingelheim has developed and now implemented a flexible set-up and operational approach for disposable technologies within its global biopharmaceutical development and manufacturing network.
Regardless of which single use system has been used by customers, Boehringer Ingelheim's disposable set-up enables that different commercially available single use systems can be operated in the same facility and by the same experts. Boehringer Ingelheim BioXcellence's™ customers now benefit from an unprecedented level of flexibility while maintaining reliable and efficient project transfers. Besides the novel 100L and 500L GMP (good manufacturing practice) facilities for clinical material supplies the same set-up is in operation for non-GMP process development.
"We have gathered years of experiences from different single use systems in our expert groups and could therefore form a truly unique single use platform for upstream- and downstream processes", commented Hitto Kaufmann, Vice President Process Science Germany at Boehringer Ingelheim Biopharmaceuticals."
This platform will be established globally in Boehringer Ingelheim's mammalian facilities and will support clients globally with the same technology as well as quality standards. It will significantly ease seamless process transfers, smooth outsourcing concepts and further boosts our new and highly flexible Lean-to-Clinic program from gene to drug product in 16 months ".
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro.
Boehringer Ingelheim Biopharma Contract Manufacturing is now represented by its new brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought 19 biopharmaceutical products to market. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA).
Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.
More information:
www.bioxcellence.com